Publications scientifiques sur les diagnostics non invasifs BioPredictive
Études évaluées par les pairs validant les diagnostics sanguins BioPredictive pour les maladies du foie — des cohortes pionnières aux méta-analyses à long terme.
186/435
Résultats pour
“FibroSure”
-
FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B.
…Our aim was to evaluate the capacity of FibroSURE, one of the…
-
Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.
…Histologic findings were correlated with FibroSure and HA results. ### Results The study…
-
An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis.
…The testing strategies included a testing algorithm using the Fibrosure test, a…
-
Letter: APRI and FIB-4 do not correlate with Fibrosure in the evaluation of liver fibrosis in hepatitis C patients.
-
Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.
…Among the 107 patients who underwent NASH FibroSure testing during MTX therapy…
-
Progression of liver fibrosis among injection drug users with chronic hepatitis C.
…Predictive values of blood markers [FibroSURE, aspartate aminotransferase-to-platelet-ratio index…
-
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
…This study compared two commercially available serum marker panels (HCV FibroSURE and…
-
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.
…Performance of Fibrotest-Fibrosure was good in all aetiologies for both ≥F2…
-
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
…The study population was subdivided according to baseline FibroSURE test results into…
-
FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.
…or 48 (genotype 1) wk. FibroSURE™ (FS) was assessed at baseline and…
-
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.
…platelet ratio index and Fibrotest-Fibrosure, thereby limiting liver biopsy to cases…
-
Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.
…serum testosterone and perform the FibroSURE-ActiTest. Other risk-factor data were…
-
FibroMAX: towards a new universal biomarker of liver disease? Review
…as HCV-FibroSURE, HBV-FibroSURE, ASH-FibroSURE and NASH-FibroSURE; LabCorp, NC…
-
Finasteride and methadone use and risk of advanced hepatitis C related liver disease.
…and hepatic pathology by the FibroSURE-ActiTest (F3/F4-F4, advanced vs…
-
Liver fibrosis in adults with Fontan palliation: Do common screening studies predict disease severity?
-
Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.
…the diagnostic performance of the FibroSURE (FS) index and collagen/alpha smooth…
-
FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?
…assessment of necroinflammatory activity (HCV-FibroSURE, LabCorp). The possible causes of false…
-
Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.
…Methods We used the validated FibroSURE-ActiTest to assess hepatic pathology, and…
-
An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.
**Background:** The current definition of metabolic dysfunction-associated steatotic liver disease (MASLD…
-
FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Meta Analysis
…Noninvasive alternatives such as FibroTest/Fibrosure (FT) have been developed in order…
-
Biopsy as well as FibroTest/Fibrosure is suboptimal for discriminating intermediate fibrosis stages in patients with chronic hepatitis B.
-
Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.
…We defined cirrhosis with the FibroSure test (F3/4-F4). We used…
-
Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.
…hepatic fibrosis, based on the FibroSURE test (BioPredictive, Paris, France) (F0-F3…
-
Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Meta Analysis
…liver fibrosis (ELF) and FibroTest (FibroSure in the USA). ### Results Forty-five…
-
Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.
…liver biopsy examination and FibroTest FibroSure (FT) results were included prospectively. Fibrosis…
-
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
…usefulness of biochemical markers (Fibrotest-Fibrosure/ActiTest [FT-AT]) in aged patients…
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication Review
This review summarizes the methodological aspects of the interpretation of non-invasive…
-
Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes.
### Background & Aims Patients with diabetes are at risk for nonalcoholic fatty liver…
-
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication
### Background Liver biopsy is considered as the gold standard for assessing non…
-
The non-invasive assessment of hepatic fibrosis. Review
Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…
-
A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.
In therapy with standard interferon and ribavirin, five independent risk factors (RF…
-
Assessment of liver fibrosis: noninvasive means.
Liver biopsy, owing to its limitations and risks, is an imperfect gold…
-
The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.
…transient elastography (TE) and FibroTest (FibroSURE in the United States), an indirect…
-
Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.
A serum biomarker (FibroTest; Biopredictive, Paris, France; FibroSure; LabCorp, Burlington, USA) and…
-
Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.
### Background/Aims According to guidelines, the histological diagnosis of severe alcoholic steatohepatitis…
-
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
### Background & Aims Chronic hepatitis C is both a virologic and fibrotic disease…
-
Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).
### Background & Aims The first aim was to extend the validation of FibroTest…
-
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Key publication
### Background One of the unmet needs in patients with metabolic risks is…
-
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication
### Background Liver biopsy is considered the gold standard for assessing histologic lesions…
-
Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.
### Background And Aims Chronic hepatitis C (HCV) is a liver disease affecting…
-
Biomarkers of liver fibrosis. Review
Liver biopsy, due to its limitations and risks, is an imperfect gold…
-
Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?
-
Comparison of noninvasive models of fibrosis in chronic hepatitis B.
### Background And Goals Liver fibrosis influences treatment and surveillance strategies in chronic…
-
Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication Review
-
Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.
### Background Mortality related to complications of cirrhosis is increasing in patients with…
-
Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.
### Background FibroTest has been validated for the diagnosis of liver fibrosis in…
-
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
### Background & Aims Time-dependent statistics have been used to assess liver fibrosis…
-
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication
### Background Biopsy is the usual gold standard for liver steatosis assessment. The…
-
The role of the non-invasive serum marker FibroTest-ActiTest in the prediction of histological stage of fibrosis and activity in children with naïve chronic hepatitis B infection.
The aim of this study was to investigate whether the non-invasive…
-
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication
The aim was to assess the utility of FibroTest-ActiTest (FT-AT…
-
Poynard T, Imbert-Bismut F, Ratziu V, Myers RP, Di Martino V, Thabut D, Moussalli J, Benhamou Y
-
Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?
-
Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.
### Background & Aims There is controversy about the performance of noninvasive tests such…
-
Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.
### Aim To assess the diagnostic value of Fibrotest in comparison with liver…
-
Non-invasive markers for hepatic fibrosis. Review
With great advancements in the therapeutic modalities used for the treatment of…
-
Meta-analyses of FibroTest diagnostic value in chronic liver disease. Key publication Meta Analysis
### Background FibroTest (FT) is a biomarker of liver fibrosis initially validated in…
-
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.
### Background The area under the receiver operating characteristic (ROC) curve is widely…
-
Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. Meta Analysis
### Background Accurately staging hepatitis C virus (HCV)-related fibrosis is crucial for…
-
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. Review
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…
-
Effective use of FibroTest to generate decision trees in hepatitis C.
### Aim To assess the usefulness of FibroTest to forecast scores by constructing…
-
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.
SUMMARY: BACKGROUND: Recent studies strongly suggest that due to the limitations and…
-
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Key publication
### Background Blood tests of liver injury are less well validated in non…
-
The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.
### Aim To assess the diagnostic value of FibroTest to discriminate between insignificant…
-
Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations.
-
Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.
Fontan-associated liver disease (FALD) is a serious complication related to the…
-
FibroTest (FT) has similar accuracy for cirrhosis in 'intention-to-diagnose' which is superior to transient elastography (TE) in chronic hepatitis B.
-
Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis.
### Background Methotrexate (MTX) use is associated with hepatic fibrosis in psoriasis patients…
-
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Key publication
**Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…
-
The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases.
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.
-
FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases.
-
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Key publication
### Background The area under the ROC curve (AUC) is widely used as…
-
HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C.
### Background And Aim Three gene polymorphisms, interferon-lambda-3 (IL28B), inosinetriphosphatase (ITPA…
-
Hepatitis C virus viremia and low platelet count: a study in a hepatitis B & C endemic area in Taiwan.
### Background & Aims Hepatitis C virus (HCV) infection has been shown to be…
-
Optimal correlation between different instruments for Fibrotest-Actitest protein measurement in patients with chronic hepatitis C.
### Objectives Combination of alpha 2-macroglobulin, haptoglobin, apolipoprotein-A1, gamma-glutamyl transpeptidase…
-
FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication Meta Analysis
FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…
-
Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.
### Background Assessing liver fibrosis is traditionally performed by biopsy, an imperfect gold…
-
The risk of multiplying diagnostic combinations in the absence of a perfect gold standard for a fibrosis test.
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Key publication
In patients with non-alcoholic fatty liver disease (NAFLD) with or without…
-
Prospective noninvasive analysis of hepatic fibrosis in patients with Crohn's disease: correlation of transient elastography and laboratory-based markers.
### Background And Aims Hepatobiliary disorders, associated either with extraintestinal manifestations or with…
-
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
Fibromax is a diagnostic tool composed of the combination of 4 non…
-
Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Review
### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…
-
[The value of noninvasive serological markers in hepatitis B]. Review
Bloodless methods (serological and imaging) for evaluating hepatic fibrosis constitute a good…
-
Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.
### Background & Aims Liver fibrosis stage is traditionally assessed with biopsy, an imperfect…
-
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. Key publication
### Background One of the unmet needs in patients with type 2 diabetes…
-
Toward non-invasive assessment strategies in autoimmune hepatitis.
In this article, we comment on the article by Peta _et al…
-
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Review
### Background Chronic HCV is one of the major causes of morbidity and…
-
Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations.
The relationship between nonalcoholic fatty liver disease (NAFLD) and obstructive sleep apnea…
-
The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. Key publication
### Background/Aims The aim was to identify a panel of biomarkers (AshTest…
-
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.
### Background & Aims Therapeutic options for patients failing hepatitis C retreatment are limited…
-
Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.
### Background And Aims Real-time shear wave elastography (2D-SWE) is a…
-
Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. Review
Patients with HIV have a proclivity to develop liver fibrosis, especially when…
-
FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Meta Analysis
### Background The accurate diagnosis of hepatitis C virus (HCV)-related fibrosis is…
-
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.
### Objectives The noninvasive serum markers, FibroTest-ActiTest (FT-AT), are an alternative…
-
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).
### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…
-
Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C.
The aim of this study was to compare the results of nine…
-
Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference. Key publication
-
Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.
### Background The Fibrotest-Actitest is a six-parameter scoring system that allows…
-
[SWE elastography in assessment of liver fibrosis]. Review
Liver fibrosis is a relatively common consequence of chronic liver diseases, especially…
-
Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis B and C.
### Aims FibroTest and ActiTest are noninvasive tests used in determining the level…
-
Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Meta Analysis
### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.
### Background Many blood tests have been proposed as alternatives to liver biopsy…
-
PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.
### Context Recently, it has been shown that an allele in the adiponutrin…
-
Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Review
Chronic hepatitis B virus (HBV) infection is a major cause of liver…
-
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.
### Aims To evaluate the application of the recently proposed recommendations by the…
-
The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B.
### Background The Fib-4 index is a simple and inexpensive biomarker to…
-
[Biomarkers for liver fibrosis: advances, advantages and disadvantages]. Review
Liver cirrhosis in Mexico is one of the most important causes of…
-
Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.
### Background Hepatitis C virus (HCV) is a major cause of chronic hepatitis…
-
Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience.
### Background The aim of this study was to compare noninvasive biomarkers, FibroTest…
-
Concordance of non-invasive serology-based scoring indices and transient elastography for liver fibrosis and cirrhosis in chronic hepatitis C.
Aim To assess concordance of eight frequently used serology-based scoring indices…
-
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
### Background & Objectives One of the multiple factors contributing to virological response in…
-
Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection. Key publication
FibroTest-ActiTest (FT-AT) has been validated in adults with chronic hepatitis…
-
Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C.
### Background Liver biopsy is an imperfect gold standard for assessing the disease…
-
Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.
### Background The main causes of liver fibrosis in transfusion-dependent thalassemia major…
-
Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study.
### Background And Aims Primary prevention of variceal bleeding with beta-blockers improves…
-
Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.
### Background/Aims Non-invasive markers of liver fibrosis have recently been developed…
-
Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.
The aim of this study was to evaluate the diagnostic values of…
-
ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Meta Analysis
### Background ActiTest (AT) is a biomarker of liver necro-inflammatory histological activity…
-
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.
### Background And Aim Significant hepatic fibrosis is prognostic of liver morbidity and…
-
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.
### Background FibroTest (FT) is the most frequently used serum fibrosis marker and…
-
Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers.
### Objective Studies have shown that patients with failing Fontan circulation may develop…
-
Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
### Background Liver biopsy is considered as the gold standard for assessing nonalcoholic…
-
Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.
### Objective And Methods We assessed the reliability of non-invasive biological scoring…
-
Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.
### Aim To assess the performance of several non-invasive markers and of…
-
Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".
### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…
-
Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. Key publication
### Background The efficiency of transient elastography for the assessment of liver fibrosis…
-
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. Meta Analysis
### Background Liver biopsy is considered as the gold standard for assessing non…
-
Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. Review
### Background Liver fibrosis is a sign of advanced liver disease and is…
-
Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography.
### Background Progression of recurrent hepatitis C is accelerated in liver transplant recipients…
-
Relationship between the Fibrotest and portal hypertension in patients with liver disease.
### Background The best technique to estimate portal hypertension (PHT) is to measure…
-
Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients.
### Background The prediction of fibrosis is an essential part of the assessment…
-
Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.
### Introduction Non-invasive, i.e. serum-based assessment of liver fibrosis is…
-
Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.
### Objective Chronic viral hepatitis B and C cause liver fibrosis, leading to…
-
Impact of steatosis and inflammation definitions on the performance of NASH tests.
### Background And Aim One of the unmet needs in subjects with metabolic…
-
Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Key publication
### Objectives Fibrotest (FT) and Actitest (AT) are biochemical markers of fibrosis and…
-
[Results transferability on RXL, ARX, X-Pand, BN2 (Dade Behring) and modular DP (Roche Diagnostics) analysers: application to component assays of fibrotest and Actitest].
The follow up of patients with chronic liver diseases and the data…
-
Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests.
### Objective To evaluate the rates of reliable diagnosis of cirrhosis by two…
-
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Key publication
### Background Although the FibroTest has been validated as a biomarker to determine…
-
Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.
### Background & Aims Real-time shear wave elastography (SWE) is a new two…
-
Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.
### Background And Aims Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are…
-
Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.
### Background And Aims The PGAA index was one of the first composite…
-
Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.
### Background Liver stiffness and non-invasive tests predict overall survival in chronic…
-
Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.
Nonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the…
-
A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Key publication
### Background FibroTest, a noninvasive method of measuring biomarkers of liver fibrosis, is…
-
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication
FibroTest has been validated as a biomarker of fibrosis in patients with…
-
Optimization and robustness of blood tests for liver fibrosis and cirrhosis.
### Objectives To optimize the performance and feasibility of fibrosis blood tests and…
-
A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C.
### Objectives Precise evaluation of the level of liver fibrosis is recommended in…
-
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
### Objective The 2019 _Standards of Medical Care in Diabetes_ suggested that patients…
-
Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.
### Background/Aims The aim of this study was to compare the performance…
-
Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
### Background HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver…
-
Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.
### Objectives : Progressive liver injury is a concern in HIV-infected children exposed…
-
The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.
### Background And Aim The validity of biomarkers of excessive alcohol drinking (EAD…
-
Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
### Unlabelled The association of NAFLD with chronic hepatitis C (CHC) has been…
-
[Alpha 2 macroglobulin immunoturbidimetric assays (DakoCytomation reagents) on Roche Diagnostic analysers (Modular P, Cobas Integra). Application to FibroTest-Actic-Test].
### Background Alpha2Macroglobulin (A2M) measure showed a revival since it was introduced into…
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
Chronic hepatitis C remains a significant medical and economic burden in Canada…
-
Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.
### Background Recent longitudinal studies have emphasised the prognostic value of noninvasive tests…
-
Hepatic and renal end-organ damage in the Fontan circulation: A report from the Australian and New Zealand Fontan Registry.
### Background Hepatic and renal dysfunction have been observed in survivors of the…
-
The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).
The aim of this study was to evaluate the diagnostic usefulness of…
-
Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.
### Background The efficacy of a maintenance therapy in non-responder patients with…
-
Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C.
### Background Non-invasive tests have been constructed and evaluated mainly for binary…
-
Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.
### Background FibroTest (FT) is a validated biomarker of fibrosis. To assess the…
-
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
### Background & Aims Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with…
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
### Background Excessive alcohol consumption may lead to the development of alcohol-related…
-
Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.
Noninvasive indexes have been developed to predict fibrosis staging. The aim of…
-
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.
### Background & Aims EPIC-3 is a prospective, international study that has demonstrated…
-
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
### Background & Aims FibroTest™ (FT) and Transient Elastography (TE) have been validated as…
-
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.
### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…
-
Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication
Liver fibrosis is a common pathway leading to cirrhosis, which is the…
-
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. Key publication
### Objective There is a controversy about the performance of blood tests for…
-
Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.
### Background & Aims Noninvasive tests (NITs) of liver fibrosis have been suggested to…
-
Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.
### Background Preliminary data suggest that performance of non-invasive markers for liver…
-
Biomarkers for liver disease in urea cycle disorders.
### Background Urea cycle disorders (UCDs) are among the most common inborn errors…
-
Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
### Background And Aim Mortality of alcohol-related liver disease (ArLD) is increasing…
-
Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Meta Analysis
### Background Liver biopsy and virological end points are standard references for assessing…
-
Noninvasive Assessment of Liver Fibrosis. Key publication Review
-
Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review
Even though alcohol-related liver disease (ALD) is a major cause of…
-
Noninvasive evaluation of NAFLD. Review
A common clinical concern in patients with NAFLD is whether they have…
-
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Review
The correct identification of patients at increased risk of non-alcoholic steatohepatitis…
-
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review
Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…
-
Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. Review
The limitations of liver biopsy (invasive procedure, sampling errors, inter-observer variability…
-
Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication
### Background Since 1920, a decrease in serum cholesterol has been identified as…
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.
### Introduction A prognostic model to predict liver severity in people with metabolic…
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection
These are the first World Health Organization (WHO) guidelines for the prevention…
-
Prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C — Rapport de recommandations 2014 Key publication
Affichage de la liste complète des résultats. La page est rendue côté serveur et non paginée.